Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131636 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT02131636 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 440 participants.
The verdict
NCT02131636, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
Interventions
- DRUG AGN-199201
- DRUG Vehicle to AGN-199201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02131636
The ClinicalTrials.gov registry entry for NCT02131636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGN-199201 is the first listed.
NCT02131636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02131636 about?
NCT02131636 is a clinical study titled "Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea". This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
What is the current status of trial NCT02131636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2014-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02131636?
The interventions under investigation include: AGN-199201 (DRUG), Vehicle to AGN-199201 (DRUG).
Who is sponsoring clinical trial NCT02131636?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.